Industry veteran joins Auxilium Pharmaceuticals

Adrian Adams succeeds Armando Anido at the US firm

Auxilium Pharmaceuticals, a specialist biopharmaceutical company based in Malvern, PA, US, has appointed Adrian Adams as chief executive and president, effective immediately. Adams succeeds Armando Anido, who has agreed to step down and has resigned as a member of the Board. Adams will also succeed him on the Board.

Adams has more than 30 years of experience in the pharmaceutical industry, most recently serving as chairman and ceo of Neurologix, a biotechnology company engaged in the development of gene therapies for disorders of the brain and central nervous system. Prior to that, he was president and ceo of Inspire Pharmaceuticals, where he oversaw the development and commercialisation of prescription pharmaceutical products and led the company through a strategic acquisition by Merck & Co.

Before joining Inspire, Adams was president and ceo of Sepracor until its acquisition by Dainippon Sumitomo Pharma Co in 2010. Prior to this, he was president and ceo of Kos Pharmaceuticals from 2002 until the company was acquired by Abbott Laboratories in 2006.

Adams has also held general management and senior international and national marketing positions at Novartis, SmithKline Beecham and ICI (now part of AstraZeneca).

You may also like

Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Pharmaceutical

Samsung Bioepis expands European biosimilar portfolio with OBODENCE and XBRYK launches

The products, targeting osteoporosis and bone-related complications in cancer, strengthen access to affordable care and expand the company’s direct sales footprint across endocrinology and oncology
Regulatory

EU approves Sanofi and Regeneron’s Dupixent as first targeted CSU treatment in more than a decade

The European Commission has authorised Dupixent for moderate-to-severe chronic spontaneous urticaria in patients aged 12+, offering the first new targeted option in more than ten years
Regulatory

FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment

The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Sustainability

Solvent recyclers improve HPLC system sustainability

A leading pharmaceutical company has purchased 17 SPR-200 solvent recycler units from Biotech Fluidics improving sustainable use of solvents by HPLC systems in their analytical laboratories
Pharmaceutical

Polpharma Biologics announces US launch of Tyruko, the first FDA-approved natalizumab biosimilar for MS

Tyruko is now available to US patients with multiple sclerosis and Crohn’s disease, expanding access to a more affordable biologic option
Research & Development

Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development

Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies
Subscribe now